Cubist Completes Purchase of Trius

September 12, 2013 | Cubist Pharmaceuticals has completed a $704 million acquisition of Trius Therapeutics. Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Trius Therapeutics focuses on antibiotics. UT San Diego; Background via Bloomberg